Clinical Trials Logo

Clinical Trial Summary

To explore the genetic background of patients with HER2 positive breast cancer that benefit from trastuzumab combined with neoadjuvant chemotherapy, identify clinically actionable mutations that associated with trastuzumab resistance or drug efficacy, we designed this Observational phase II trial. The primary endpoint is genetic profile of HER2+ breast cancer patients treated with trastuzumab combined neoadjuvant chemotherapy. Secondary endpoints included pathological complete response (pCR) rate and safety.


Clinical Trial Description

Currently, patients with stage II-III breast cancer still accounts for a large population in China, and neoadjuvant therapy is considered the standard treatment for them. The pathological complete response (pCR) rate takes for an indicator for regimens efficacy, and the achievement of pCR after neoadjuvant chemotherapy is associated with favorable outcomes including disease-free survival and overall survival. HER2+ breast cancer represents an invasive and poor prognosis subtype, and the efficacy of neoadjuvant therapy for these patients has been greatly augmented by the addition of trastuzumab. However, more than 50% of HER2+ breast cancer patients treated with trastuzumab combined neoadjuvant chemotherapy cannot achieve pCR, even experience primary drug resistance and rapid disease progression. Therefore, to explore the genomic features of the population that benefited from trastuzumab combined with chemotherapy is of great significance for personalized treatment of HER2+ breast cancer, aiming to avoid overtreatment and identify clinically actionable mutations for future therapy instructions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03728829
Study type Observational
Source Hebei Medical University Fourth Hospital
Contact Yunjiang Liu, MD, PhD
Phone +86-311-8609-5588
Email lyj818326@126.com
Status Recruiting
Phase
Start date July 2021
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01168570 - Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level N/A
Completed NCT03548753 - Use of FFR-CT in Stable Intermediate Chest Pain Patients With Severe Coronary Calcium Score
Completed NCT03138772 - Tracking CF Lung Disease Through the Early Years: Utility of the LCI
Completed NCT00233649 - DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines Phase 4
Completed NCT06433154 - Arthroscopy of the Temporomandibular Joint. On Jaw Mobility, Pain and HRQoL
Not yet recruiting NCT06448715 - Real-World Treatment Study of Soliris (Eculizumab)
Completed NCT00745966 - Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder N/A
Recruiting NCT03253536 - Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma N/A
Not yet recruiting NCT05693714 - Adenovirus Infection in Children With Autoimmune Hepatitis
Completed NCT02922205 - Stapler Post-market Observational Study